29 January 2026
EMADOC-1700519818-2852304
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Eurneffy

epinephrine

On 29 January 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Eurneffy. The marketing authorisation holder for this medicinal product is ALK-Abelló A/S.

The CHMP adopted a new strength, 1 mg nasal spray, associated with an extension to the existing indication, as follows:[2]

> EURneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children **aged 4 years and over** with a body weight **of 15 kg or more** ~~≥30 kg~~.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union